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Abstract.  The ability of single subunit chimeric 
receptors containing various integrin fl intracellular 
domains to mimic and/or inhibit endogenous integrin 
function was examined. Chimeric receptors consisting 
of the extracellular and transmembrane domains of the 
small subunit of the human interleukin-2 receptor con- 
nected to either the fl~, f13, fl3B, or r5 intracellular do- 
main were transiently expressed in normal human 
fibroblasts.  When expressed at relatively low levels, 
the r3 and r5 chimeras mimicked endogenous ligand- 
occupied integrins and, like the fl~ chimera 
(LaFlamme, S. E.,  S. K.  Akiyama, and K.  M. 
Yamada.  1992.  J.  Cell Biol.  117:437),  concentrated 
with endogenous integrins in focal adhesions and sites 
of fibronectin fibril formation. In contrast, the chi- 
meric receptor containing the fl3s intracellular domain 
(a r3 intracellular domain modified by alternative 
splicing) was expressed diffusely on the cell surface, 
indicating that alternative splicing can regulate integrin 
receptor distribution by an intraceUular mechanism. 
Furthermore, when expressed at higher levels, the fl~ 
and r3 chimeric receptors functioned as dominant 
negative mutants and inhibited endogenous integrin 
function in localization to fibronectin fibrils, fibronec- 
tin matrix assembly, cell spreading, and cell migra- 
tion. The r5 chimera was a less effective inhibitor, and 
the fl3B chimera and the reporter lacking an intracellu- 
lar domain did not inhibit endogenous integrin func- 
tion. Comparison of the relative levels of expression of 
the transfected fll chimera and the endogenous fl~ 
subunit indicated that in 10 to  15h assays, the fll chi- 
mera can inhibit cell spreading when expressed at lev- 
els approximately equal to to the endogenous/3~ 
subunit. Levels of chimeric receptor expression that 
inhibited cell spreading also inhibited cell migration, 
whereas lower levels were able to inhibit otsfl~ localiza- 
tion to fibrils and matrix assembly. 
Our results indicate that single subunit chimeric 
integrins can mimic and/or inhibit endogenous integrin 
receptor function, presumably by interacting with cy- 
toplasmic components critical for endogenous integrin 
function. Our results also demonstrate that fl intracel- 
lular domains, expressed in this context, display 
specificity in their abilities to mimic and inhibit en- 
dogenous integrin function. Furthermore, the approach 
that we have used permits the analysis of intracellular 
domain function in the processes of cell spreading, 
migration and extracellular matrix assembly indepen- 
dent of effects due to the rest of integrin dimers. This 
approach should prove valuable in the further analysis 
of integrin intracellular domain function in these and 
other integrin-mediated processes requiring the inter- 
action of integrins with cytoplasmic components. 
I 
NTEGRINS comprise the major class of receptors used 
by cells to interact with the extracellular matrix. Al- 
though some integrins are cell-type specific, most inte- 
grins are expressed in a variety of cell types, providing cells 
with the ability to interact with many different extracellular 
matrix proteins in a variety of cellular processes. Depending 
upon the type of cell, integrins can function in cell adhesion, 
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cell spreading, and cytoskeletal organization, cell migration, 
matrix assembly, and signal transduction,  thereby playing 
important roles in embryonic development,  would healing, 
tumor metastasis, tissue organization, and differentiation (2, 
3,  14,  16, 24, 30, 32, 33, 36, 54). 
Integrins are cdfl heterodimeric transmembrane proteins. 
The ct and fl subunits generally contain short cytoplasmic 
domains that are believed to interact with the cytoskeleton 
and other cytoplasmic components to mediate and regulate 
integrin function in response to the extracellular matrix (56). 
Molecular genetic approaches  are currently being used to 
define  specific  functions  for  individual  intraceUular  do- 
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mutant  intracellular domains have been expressed in other 
species  or  in  cell  lines  lacking  the  expression  of  the 
corresponding  endogenous  subunit  in  order  to  study  the 
function of particular  intracellular domains in the context of 
heterodimeric  receptors.  Roles  have  been  defined  in  this 
manner for o~ intracellular domains in modulating integrin 
function in cell adhesion,  migration,  collagen gel contrac- 
tion (7,  12, 37, 38), and in the regulation of affinity  state of 
the platelet integrin, Olllb~3 (48, 49).  Requirements for/3 in- 
tracellular  domain  function  have  similarly  been  demon- 
strated  for cell adhesion (29,  31),  cell spreading  (69),  inte- 
grin localization to focal adhesions (29, 42, 62, 69), and the 
adhesion-dependent  phosphorylation  of the  focal adhesion 
kinase pp125  FAK  (27,  28,  57). 
An alternative  approach to studying integrin intracellular 
function is to analyze the function of integrin intracellular 
domains expressed as separate  domains connected to an ex- 
tracellular reporter and transmembrane domain. Using this 
approach,  we and others have demonstrated that the/3t  in- 
tracellular domain can function as a separate domain and can 
direct the localization of a reporter  to focal adhesions  (23, 
39), presumably by an intracellular mechanism involving an 
intrinsic  ability  of the/3~  intracellular  domain  to  bind  to 
cytoskeletal proteins that bind to endogenous integrins con- 
centrated at these adhesion sites. The intrinsic ability of the 
/3 intracellular domain to concentrate at focal adhesions ap- 
pears to be regulated in endogenous integrins by ligand oc- 
cupancy in a process involving the a  intracellular domain (8, 
39, 69). 
These observations suggest the hypothesis that/3  intracel- 
lular domains, expressed in the absence of their correspond- 
ing  ot  intracellular  domains,  bind  to  similar  cytoplasmic 
components as ligand-occupied integrins. If this hypothesis 
were correct, then when expressed at relatively low levels, 
single subunit  chimeric receptors containing/3 intracellular 
domains should mimic endogenous integrin function, and at 
higher levels of expression they should inhibit endogenous 
integrin  function  by  titrating  out  required  cytoplasmic 
component(s). In addition, because various/3 integrin intra- 
cellular domains differ in their primary structure  and these 
differences  among  integrin  /3  subunits  are  evolutionarily 
conserved, individual/3 intracellular domains may differ in 
the functions that they can affect. We have tested this hypoth- 
esis by  expressing/3  intracellular domains  connected to a 
reporter domain and analyzing their abilities to mimic or in- 
hibit various aspects of integrin receptor function. Using this 
approach, we have compared the ability of/3 intraceUular do- 
mains to direct receptor localization to focal adhesions and 
have defined a role for alternative  splicing in regulating  this 
process. Furthermore, we demonstrate that when expressed 
at relatively high levels, B chimeras can function as dominant 
negative mutants.  Specifically, they can inhibit endogenous 
integrin  function  in  cell  spreading,  cell  migration,  and 
extracellular  matrix  assembly,  and  they  show  functional 
specificity dependent upon the cytoplasmic domain present. 
Materials and Methods 
Construction of Chimeric Receptors 
Chimeric receptors were constructed using standard molecular biological 
techniques (55).  DNAs encoding the various/3 intracellular domains were 
generated by the polymerase chain reaction,  using PCR kits from Perkin- 
Elmer Corp. (Norwalk,  CT), and were then inserted as HindIII-XhoI re- 
striction fragments into the previously  described plasmid vector encoding 
the control receptor,  consisting of the extracellular and transmembrane do- 
mains of the intedeukln-2 (IL-2) l receptor,  in place of its single intracellu- 
lar lysine residue (39).  The integrity of each construct was confirmed by 
nucleotide  sequence analysis.  The/33 and/35  intracellular domains were 
amplified  from a human embryonic lung fibroblast eDNA library. The/33s 
intracellular domain was also generated by the polymerase chain reaction 
using as template the/33 chimera and a COOH-terminal primer encoding 
the amino acids modified by alternative splicing.  Oligonucleotide  primers 
also encoded either an NHa-terminal HindIII restriction site or a COOH- 
terminal XhoI restriction site,  so that resulting DNAs could easily be in- 
serted as HindIII-XhoI  restriction fragments.  The oligonucleotide  primers 
for the/33  intracellular domain were as follows: 
NH2-terminal primer:  5'-GCCCTGCTCATCTGGAAGCTTCTCATCACC-Y 
COOH-ternfinal primer: 5'-AGCGACCTCGAGTTAAGTGCCCCGGTAC- 
GTGATA'I~T-3'. 
The  oligonucleotide  primers  for  the  /35  intracellular domain  were  as 
follows: 
NH2-terminal  primer:  5'-CTGGAAGCTTCTTGTCACCATCCACGAC- 
CGG-Y 
COOH-terminal  primer:  5'-GACCTCGAGTCAGTCCACAGTGCCAT- 
TGTAGG-3'. 
The oligonucleotide  primers for/33B intracellular domain were as follows: 
NH2-terminal  primer: 5'-GGCTCACCTGGAAGCTTCTCATC-3' 
COOH-terminal primer:  5'-AGCGACCTCGAGTCAGAGCAATGACTTT- 
AGAAAAC  GCCCAGC CCC GTCTCTTACTGTGTCCCATTTTGCTCT- 
GGC-3'. 
Cells and Transfections 
Normal human foreskin  fibroblasts,  a generous gift from Dr. Steven Alex- 
ander (Bethesda Research Laboratories, Gaithersburg, MD), were cultured 
in DME supplemented with 1 mM glutamine, 50 ftg/ml streptomycin,  50 
U/ml penicillin, and 10% heat-inactivated  FCS.  Electroporation of these 
cells was performed as previously described (25, 26) at 170 V and 960 mF 
with a Bio-Rad  Gene Pulser (Bio-Rad  Laboratories, Richmond, CA),  ex- 
cept 15 to 30/~g of DNA was used per transfection.  Lower concentrations 
of DNA resulted in fewer transfected cells and a lower level of expression 
compared with higher concentrations of DNA. 
Antibodies and Purified Proteins 
Laminin was generously provided by Dr. Hynda Kleinman (National Insti- 
tutes of Health, Bethesda, MD). Collagen I (Vitrogen 100) was purchased 
from Collagen Corp.  (PUlo Alto, CA). Human plasma fibronectin was iso- 
lated as previously described (44). Vitronectin was generously provided by 
Drs.  Steven Aklyama (National Institutes of Health)  and David Cheresh 
(Scripps Research Institute, La Jolla, CA). The polyclonal antibody R3134 
to the small subunit of the IL-2 receptor (59)  was a generous gift of Dr. 
Warren Leonard (National  Institutes of Health)  and the mouse mAb 4E3, 
also directed against the small subunit of the IL-2 receptor,  was purchased 
from Boehringer Mannheim Biochemicals (Indianapolis,  IN). Mouse mAb 
7G7B6 (American lype Culture Collection, Rockville,  MD) was purified 
from ascites by sequential ammonium sulfate precipitation, passage through 
a DE 52 column (Whatman, Hillsboro,  OR) in 30 mM NaC1,  10 mM so- 
dium  phosphate,  pH  7.4,  and  then  affinity chromatography  on  protein 
A-Sepharose (Pharmacia Fine Chemicals, Piseataway, NJ). mAb 13 to the 
/3t  subunit and  goat  anti-human fibronectin antibodies directly labeled 
with FITC have been previously  described (1); mAb 11 to the ct5 subunit 
was  generously  provided by Dr.  Steven  Aklyama (National Institutes of 
Health); mouse mAb to the/31  subunit was purchased from Amac, Inc. 
(Westbrook,  ME).  F1TC- and rhodamine-labeled second antibodies were 
purchased from Rockland, Inc. (Gilbertwille, PA) and Tago, Inc.  (Burlin- 
game,  CA). 
1. Abbreviations used in this paper: AU, arbitrary units; IL-2, interieukin 2. 
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Reflection Microscopy 
Cells were cultured on glass coverslips as indicated, fixed for 30 to 60 min 
with 4% formaldehyde, 5% sucrose in Dulbecco's PBS, and then washed 
several times in PBS, permeabilized for 5 min in 0.2 % Triton X-100 in PBS, 
washed several times with PBS, incubated for 30 rain in 3% BSA, 0.1% gly- 
cine (pH 7.5) to block nonspecific binding, washed once in PBS, incubated 
for I h at ambient temperature with primary antibody in PBS with 1 mg/ml 
BSA, washed for 30 rain in PBS with gentle agitation with several changes 
of  PBS, incubated with the appropriate FITC- or rhodamine-conjugated sec- 
ond antibody, and then washed as above. The coverglasses were mounted 
on microscope slides with 10%  glycerol in PBS containing 1 mg/ml 1,4- 
phenylenediamine (Fluka Chemical Corp., Ronkonkoma, NY) to inhibit 
photobleaching (35)  and  then  viewed on a  Zeiss photomicroscope HI 
equipped with epifluorescence and interference reflection microscopy. Im- 
munofluorescence  was photographed using Kodak TMAX 3200 film. Adhe- 
sions on the ventral cell surface were analyzed by interference reflection mi- 
croscopy (34) by standard methods using an Antiflex Neofluar 63×/NA 
1.25 objective and photographed with Kodak technical pan film processed 
with Diafine developer (Fuller and dAlbert, Inc., Falffax, VA). 
Flow Cytometry and Fluorescence Activated 
Cell Sorting (FACS) 
To compare the levels of expression of the various chimeras, transfected 
cells were harvested, washed with PBS, and incubated in a  1/100 dilution 
of FITC-conjngated anti-IL-2 receptor antibody 4E3  (Boehringer Mann- 
heim Biochemicals) for 30 rain at ambient temperature, washed with PBS, 
fixed with 2% paraformaldehyde in PBS, and then analyzed using a Becton 
Dickinson FACScan flow cytometer. 
Similarly, to compare the level of expression of the transfected/31 chi- 
mera with the endogenous/31 subunit, cells transiently expressing the/~1 
chimera were harvested, washed with PBS, divided into two aliquots, and 
then immunostained with either the mouse mAb 4E3 to the IL-2 receptor 
or the mouse mAb K20  to the/31  subunit (Amac,  Inc.).  After several 
washes in  PBS,  each aliquot  was  stained with the  same FITC-labeled 
anti-monse second antibody, washed again with PBS, and then fixed and 
analyzed by flow cytometry as described above. All antibodies were deter- 
mined to be at saturating concentrations. 
To purify cells expressing the chimeric receptors at specific levels, trans- 
fected cells were labeled with FITC-conjugated mAb 4E3 at a 1/100 dilution 
in PBS containing 1% BSA. The labeled cells were sorted into low, moder- 
ate, or high expressors by FACS under sterile conditions using a Becton 
Dickinson FACStar Plus fluorescence-activated  cell sorter and then assayed 
as described. 
Inhibition of CeU Spreading 
To compare the ability of the chimeric receptors to inhibit cell spreading 
on specific matrix proteins, cells were replated 15 h after transfection onto 
coverslips that  had  been previously coated  with 20  /~g/ml  fibronectin, 
vitronectin, or collagen I and blocked with 1% heat denatured BSA. After 
incubation for 1 h at 37°C, the cells were fixed, and then stained with mAb 
7Gr/B6 to the IL-2 receptor. 10 groups of 10 randomly selected transfected 
and nontransfected cells were analyzed by phase contrast microscopy. The 
percent inhibition for each chimeric receptor on each matrix protein was 
calculated by subtracting the percentage of nontransfected cells that were 
round from the percentage of transfected cells that were round at this time. 
To ensure that the differences in inhibition were not due to differences in 
expression levels, cell surface expression was monitored by flow cytometry. 
The ability of different chimeric receptors to inhibit cell spreading was 
also analyzed as a function of  their expression level. This was accomplished 
by two protocols: (a) Cells were transiently transfected with the different 
chimeric receptors, and 15 h after transfection  the cells were plated on colla- 
gen I-coated coverslips in 6-well tissue culture dishes for 1.5 h. Although 
the vast majority of cells from the/~3e,/~5, and control receptor transfec- 
tions were attached and spread at this time, many of the cells from the/~1 
and/33 transfections had not attached. To recover these unattached cells for 
photometric analysis, the collagen I-coated coverslips were replaced with 
coverslips coated with 20 ~g/ml concanavalin A followed by incubation for 
an additional hour at 37°C. The cells on both collagen I and concanavalin 
A-coated coverslips for each chimera were fixed and stained with mAb 4E3 
to the IL-2 receptor. The level of expression of spread and unspread cells 
was determined by photometry using a photometer system (Yona Micro- 
scope &  Instrument Co., Columbia,  MD) based on an Oriel photomul- 
tiplier (Stratford,  CT).  Photometer readings from 0  to  1,400  (arbitrary 
units, ALl) above background were obtained for each transfection, although 
very few cells had readings above 600 AU. Three expression levels were 
defined: low, from 0--150 AU; moderate, 151-300 AU; and high, 301-600 
AU. FOr each chimeric receptor, five groups of 10 randomly selected ceils 
within each expression level were scored for cell spreading. The percent in- 
hibition was calculated directly with the assumption that untransfected cells 
were 100% spread. (b) Transiently transfected cells expressing low, moder- 
ate, or high levels of specific chimeric receptors were purified by FACS. In 
one experiment, cells expressing low or high levels of the B1 chimera or 
the control receptor were purified and then incubated on unblocked plastic 
tissue culture dishes in serum-containing medium. After 15 h, the ability 
of these cells to spread was assessed by phase contrast microscopy. In a 
different experiment, cells expressing low or moderate levels of either the 
83 or B3a chimera were purified and then incubated in serum-containing 
medium. After 15  h,  these cells were replated in 96-well tissue culture 
dishes in which the weils had been previously coated with either 20/~g/ml 
fibronectin or 20/~g/ml collagen I and blocked with  1%  heat-denatured 
BSA. Cell spreading was again assessed by phase contrast microscopy. Ex- 
pression levels of chimeric receptors on the sorted cells were also analyzed 
by photometry. The mean fluorescence of the low expressors was 122 AU 
which falls within the range of fluorescence defined as low (0-150 AU) by 
photometry and the mean fluorescence of the moderate expressers was 280 
AU which falls within the range defined as moderate (151-300 AU) by pho- 
tometry. 
Cell Migration 
Normal human fibroblasts were transfected with either the ~l chimera, the 
control receptor or mock transfected. 15 h after transfection, cells express- 
iag high levels of the transfected receptors were isolated by fluorescence- 
activated cell sorting and then replated in serum-containing medium at low 
density (•2  x  104 cells) in 35 mm plastic tissue culture dishes (Costar 
Corp., Cambridge, MA), previously coated with 10/~g/ml of  human plasma 
fibronectin. The cells were maintained in growth medium in recording 
chambers at 37°C supplemented with CO2. Cell migration was recorded at 
one frame/15 rain using either the ICM 405 or Opton inverted microscope 
(Carl  Zeiss,  Oberkochen,  Germany)  equipped  with  Newvieon  Model 
C2400 video cameras (Hamamatsu Photonics, Hamamatsu City, Japan) as 
previously described (65). For each experiment, the cells to be compared 
were recorded simultaneously. Images were stored on optical discs (Pana- 
sonic models TQ 2028F or TQ3031F;  Matsushita Electronic Corp., Secau- 
cus, NJ) for later analysis. 
The migration rates (pm/h) of all cells that remained in the field of view 
for 10 h were digitized using the Track Points feature of Image 1 software 
(Universal Imaging Corp., West Chester, PA). A stage micrometer was used 
with the same microscopes, magnification, recording equipment, and moni- 
tor to standardize the scanning software to the scale of the images. Migra- 
tion rates were confirmed independently by tracing the movement of in- 
dividual cells on acetate sheets in direct contact with the video monitor. The 
tracings were then digitized with Sigma Scan software (Jandel Scientifc, 
Cone Madera, CA). 
Inhibition of a5~z Localization to Fibronectin Fibrils 
and Matrix Assembly 
Normal human fibroblasts were transiently transfected with the various chi- 
meric receptors. After 24 h, the cells were replated on 22  x  22 mm cooer- 
slips in six-well tissue culture dishes at ,~1  x  105 cells per well and then 
incubated an additional 15 h at 37°C. The cells were then fixed and the dis- 
tribution of aSfll  or fibronectin was analyzed on the cell surface of in- 
dividual nonpermeabilized transfected and nontransfected cells by double- 
label immnnofluorescence  using either: (a) FITC-labeled mouse mAb 4E3 
to the IL-2 receptor and rat mAb 11 to the a5 subunit with a rhodamine- 
labeled goat anti-rat second antibody preabsorbed with mouse IgG; or (b) 
mouse  mAb  7G7B6  to  the  IL-2  receptor  with  a  rhodamine-labeled 
anti-mouse second antibody and FITC-labeled goat polyclonal antibodies 
to fibmnectin (1). The localization of endogenous us~l was scored on in- 
dividnal cells as inhibited if it was expressed diffusely on the surface of the 
cell. Similarly, matrix assembly was scored on individual cells as inhibited 
if fibronectin was not observed in fibrils or stitches on the cell surface. For 
each transfection, 10 groups of 10 randomly selected transfected and non- 
transfected cells were scored as described above. To calculate the percent 
inhibition, the percentage of nontransfected cells with the inhibited pheno- 
type was subtracted from the percentage of transfected ceils with the in- 
hibited phenotype. These experiments were repeated several times, each 
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tained cDNA sequences of the gp55 subunit of the IL-2 receptor 
from the NH2 terminus through Trp 259 at the end of the trans- 
membrane domain  (41) connected to one of the  following: the 
cDNA sequence of (a) the B~ intracellular domain (5), (b) the/33 
intraceUular domain (21), (c) the alternatively spliced B3 intracel- 
lular domain, B3s (66), or (d) the/~5 intracellular domain (43, 51). 
The amino acids of the B intracellular domain modified by alterna- 
tive splicing are indicated in bold. 
giving similar results. Only cells spread to similar degrees that were ex- 
pressing moderate levels of the transfected chimeric receptor (as judged by 
phase contrast and immunofluoresconce  microscopy) were analyzed. In one 
experiment,  the level  of expression of the various transfeeted chimeric 
receptors was monitored quantitatively by photometry to ensure that inhibi- 
tion was being compared in cells expressing similar levels of the different 
transfected  receptors.  The  ability  of moderate  levels  of expression of 
specific chimeric receptors to inhibit matrix assembly was also determined 
in transfected cells purified by FACS as described below in the Results. 
Results 
Chimeric Receptors as Mimics of  Endogenous 
Integrins: Localization to Focal Adhesions 
Chimeric receptors (Fig. 1) were constructed containing the 
small  subunit  of  the  IL-2  receptor  as  an  extracellular 
reporter and transmembrane domain connected to either the 
83, 85, or a 83 intracellular domain modified by alternative 
splicing (66), designated 83s. A  similar chimeric receptor 
containing the 81  intracellular domain was previously de- 
scribed (39). To analyze and compare the ability of integrin 
8 intracellular domains to direct receptor localization, nor- 
Table L  Localization  of Chimeric Receptors 
Chimeric 
receptor  FN  VN  LM  COLI  Serum* 
81  +  +  +  +  + 
(39/50)  (36/50)  (46/50) 
83  +  +  +  +  "~" 
(33/50)  (35/50)  (42/50) 
83B  ..... 
(0/50)  (0/50)  (0/50) 
85  +  +  +  +  + 
(25/50)  (30/50)  (23/50) 
Transiently transfected cells were plated for 1-1.5 h on coverglasses coated 
overnight at 4°C with the indicated matrix protein and then blocked for 1 h at 
ambient temperature with 1% heat-denatured BSA. 
FN,  fibronectin;  VN,  vitronectin;  LM,  laminin;  COL  1,  type  I  collagen. 
* Transiently transfected cells were also plated on a tissue culture substrate for 
15 h in the presence of serum. +  or -  indicates the ability or inability  of the 
chimeric receptor to localize  at focal adhesions. The number of positively ex- 
pressing cells with focal adhesions that have the chimeric receptor in focal 
adhesions is given in parentheses for cells spread on FN, COL I, or plated on 
an unblocked coverslip in the presence of serum. 
mal human fibroblasts were transiently transfected with the 
various  chimeric receptors.  Transfected cells  were either 
plated on unblocked coverslips in serum-containing medium 
for 15 h, or on the specific matrix proteins fibronectin, colla- 
gen I, laminin, and vitronectin for 1-1.5 h. Since fibroblasts 
do not normally express the IL-2 receptor, the distribution 
of the chimeric receptors on the cell surface was analyzed 
by immunofluorescence using mAb 4E3 to the IL-2 receptor 
portion of the chimeric receptors. The presence or absence 
of chimeric receptors in focal adhesions was confirmed by 
interference reflection microscopy, where  focal adhesions 
appear black (34). 
The B3 and 8~ chimeric receptors concentrated at focal 
adhesions in cells cultured under all these conditions (Table 
I; Fig. 2, A and C), indicating that the B3 and 85 intracellu- 
lar domains,  like the 81 intracellular domain, also contain 
sufficient information to target a  reporter domain to focal 
adhesions formed by endogenous receptors.  However, the 
85 intracellular domain appeared to have a  lesser propen- 
sity to do so compared to the/31  and/33  intracellular do- 
mains (Table I). In contrast, the 83s chimera was expressed 
Figure 2. Localization of chimeric receptors at focal adhesions by immunofluorescence. Normal human fibroblasts transfected with the 
/33 chimera (A), the fl3s chimera (B), or the ~5 chimera (C) were plated in serum-containing medium for 15-h, and then immunostained 
with monoclonal antibody 4E3 to the IL-2 receptor portion of the chimeric receptors. Arrows indicate the location of focal adhesions. 
Each inset shows the interference reflection pattern of a portion of the cell containing focal adhesions. Bar, 10/~m. 
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receptors  with  txs/3t  at  fibronectin 
fibrils.  Normal  human  fibroblasts 
transfected  with  the  /53  chimera  (,4 
and C) or the/35 chimera (B and D) 
were  plated  in  serum-containing 
medium  for  15  h  and  then  double- 
immunostained with polyclonal anti- 
bodies to the IL-2 receptor portion of 
the chimeras (,4 and B) and mAb 11 to 
the a5 subunit of the ~5#~ fibronectin 
receptor (C and D). Arrows indicate 
examples where  the chimeric  recep- 
tors  colocalize with  the endogenous 
a5 subunit. Bar, 10 t~m. 
diffusely on the cell surface and did not concentrate in focal 
adhesions under any condition, indicating that the distribu- 
tion of the fl3B chimera was also not affected by the identity 
of  the substrate (Table I; Fig. 2 B). These results suggest that 
similar cytoplasmic interactions are involved in the localiza- 
tion of the fl~, f13, and t5 chimeras and their corresponding 
integrin receptors to focal adhesions. These results further 
suggest that  alternative  splicing  may provide a  means  of 
regulating receptor distribution, perhaps by altering the abil- 
ity  of  receptors  to  interact  with  the  cytoskeleton.  As 
documented previously (39), the control receptor lacking an 
intracellular domain was always diffuse in distribution,  as 
was the original full-length IL-2 receptor subunit (data not 
shown). 
Localization to Fibronectin Fibrils 
When  fibroblasts  are  plated  for  several  hours  in  serum- 
containing  medium,  their  ots~, fibronectin  receptors  be- 
come concentrated at sites where fibronectin fibrils associate 
with the plasma  membrane  (e.g.,  see  reference 61).  The 
cytoskeletai proteins ot-actinin, taiin, and vinculin that are 
present in focal adhesions (reviewed in reference 11) can also 
be found colocalized with fibronectin fibrils; however, the 
relative amounts of these proteins and their apposition to the 
plasma membrane may vary (9, 10, 13, 60). These cytoskele- 
tal similarities suggest that perhaps the interactions between 
integrins and the cytoskeleton are similar at focal adhesions 
and sites where fibronectin fibrils associate with the plasma 
membrane. If this notion were correct, the/33  and/~5  intra- 
cellular domains,  like the ~1  intracellular domain,  should 
also target a reporter domain to sites of fibronectin fibril as- 
sociation with the plasma membrane. To explore this possi- 
bility,  normal  human  fibroblasts  were  again  transiently 
transfected with the various chimeric receptors, plated in 
serum-containing medium for  15  h,  and then double im- 
munostained with polyclonal antibodies to the IL-2 receptor 
and mAb  11  to the cq subunit of the fibronectin receptor. 
Colocalization of the chimeric receptor with 0t5/31 at fibro- 
nectin fibrils was scored as positive if antibodies to the IL-2 
receptor colocalized with antibodies to the or5 subunit in a 
fibrillar pattern.  We found that the/33 and/35  intracellular 
domains could also direct the localization of the reporter to 
regions where fibronectin fibrils associate with the plasma 
membrane since chimeric receptors containing these intra- 
cellular domains colocalized with ot5/3, at fibronectin fibrils 
(Fig. 3). However, the/35 chimera appeared to have a lesser 
propensity to concentrate at these sites compared with the 
/3~ and/33 chimeras. When the localization of the/3t,/33, and 
/3~ chimeras  was  analyzed in 50  randomly selected ceils, 
only  17  of  50  cells  expressing  the  /35  chimera  showed 
colocalization of the/35 chimera with ot5/31 at fibrils; in con- 
trast, 40/50 and 39/50 cells showed colocalization of the/3~ 
and/33 chimeras, respectively. Unlike the other/3 chimeras, 
the/33B chimera did not colocalize with ct5/31 at these sites 
(not shown), consistent with its inability to concentrate with 
endogenous integrins at focal adhesions. 
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Figure 4. Comparison of the levels of expression of the 31 chimera 
and the endogenous 3~ subunit. The expression of the endogenous 
31 subunit and the transfected 3~ chimera were compared by flow 
cytometry. The shaded areas indicate the level of expression of the 
endogenous 3t subunit (A) or the transfected/3t chimera (B). The 
negative controls are represented by the nonshaded peaks. 
Chimeric Receptors as Dominant Negative Mutants 
We next tested the possibility that high levels of expression 
of these  chimeric  receptors  might  function  as  dominant 
negative mutants and inhibit endogenous integrin receptor 
function by competing with endogenous receptors for the 
binding of the cytoplasmic proteins required for their func- 
tion. We tested this hypothesis by analyzing the ability of 
various chimeric receptors to inhibit endogenous integrin 
receptor  function  in  receptor  localization  to  fibronectin 
fibrils, matrix assembly, cell spreading, and cell migration. 
To determine the relative levels of/3 chimera available to 
serve as  a  potential dominant negative inhibitor,  we first 
compared the level of expression of the transfected and en- 
dogenous  receptors  by  flow  cytometry  as  described  in 
Materials and Methods. Transfected cells expressed the/3m 
chimera  at  levels  from  1/10 that  of the  endogenous  /3, 
subunit  to  levels  10  times  higher  than  the  endogenous 
subunit  (Fig.  4).  Very similar  results  were also  obtained 
using combinations of either mouse or rat mAbs to the IL-2 
receptor and to the 31  subunit, and both types of analysis 
showed that over-expression of the 3t chimera does not al- 
ter cell surface expression of endogenous 3~ integrins (not 
shown). 
Inhibition of  lntegrin Receptor Function 
in Cell Spreading 
We  first  tested  the  ability  of the  3,  chimera,  when  ex- 
pressed at high levels, to function as a dominant negative 
mutant  and  inhibit  endogenous  integrin  function  in  cell 
spreading.  Normal fibroblasts were transfected with either 
the 3~ chimera or the control receptor lacking an intracellu- 
lar domain.  After 24  h,  positively expressing cells were 
sorted by FACS  into two populations:  low expressors and 
high expressors (Fig. 5, A-F). These different populations of 
sorted cells were plated separately for 15 h on unblocked tis- 
sue culture substrates in serum-containing medium.  After 
this period of time, there was no evidence of cell surface ex- 
pression of the FITC-labeled antibody originally used in the 
sorting protocol. Cells expressing either high or low levels 
of the control receptor spread and formed focal adhesions 
soon after plating (Fig. 5, G and H). Although cells express- 
ing low levels of the 31 chimera attached, spread (Fig. 5 1), 
Figure 5. Inhibition of cell spreading in cells purified by FACS. Normal human fibroblasts expressing either low or high levels of either 
the control receptor (A-C) or the 3t chimera (D-F) were purified by FACS, and then an aliquot from each sample was analyzed by flow 
cytometry (A-F). The fraction of either low expressors (L) or high expressors (H) isolated from each transfection is indicated (A and 
D). Purified cells were then plated overnight in serum-containing medium and the ability of low (G) or high (H) expression levels of 
the control receptor, or low (I) or high (J) levels of the 3, chimera to inhibit cell spreading was analyzed by phase contrast microscopy 
(G-J). Cells expressing high levels of the 3, chimera that were incubated an additional 24 h until the level of expression of the 3t chimera 
decreased (K). 
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Figure  6.  Inhibition  of  cell 
spreading on various substrate 
ligands.  Normal  human 
fibroblasts  transiently  trans- 
fected with the/st,/53,/533,  or 
the  95  chimeric  receptor or 
the control receptor,  C, lack- 
ing  an  intracellular  domain 
were  plated  in  serum-free 
medium  for 1 h on 20 #g/ml 
fibronectin  (A), vitronectin 
(B), or collagen I (C).  Cells 
were fixed and then immuno- 
stained  with  mAb 7GTB6 to 
the IL-2 receptor. The percent 
inhibition  was  calculated  as 
described  in  Materials  and 
Methods. 
and formed focal contacts (not shown), the majority of the 
high expressors remained round (Fig. 5 J). This marked in- 
hibition of cell spreading in high expressors was reversible. 
After further incubation for an additional 24 h (during which 
time the  level of expression  of the  transiently  transfected 
receptor was decreased approximately tenfold according to 
flow cytometry), the ceils expressing high levels of the/31 
chimera that were previously inhibited in cell spreading were 
now able to spread (Fig. 5 K). Similar results were also ob- 
tained when cells were transfected with the f13 chimera (not 
shown).  High expressors were apparently not immediately 
lost after transfection because the transfected cells attached 
and formed focal adhesions prior to the cell surface expres- 
sion of the transfected chimeric receptor. It is likely that the 
assembly of integrin transmembrane linkages is more easily 
inhibited than the maintenance of linkages already formed. 
We then compared the  ability of the/31,  ~3,/35,  and/~3B 
chimeras to inhibit cell spreading in short term assays on the 
specific matrix proteins, fibronectin,  collagen I, and vitro- 
nectin.  In this experiment,  cells transiently expressing the 
various chimeric receptors were not purified by FACS,  but 
were directly  incubated  on these  substrates in  serum-free 
medium for 1-1.5 h. The cells were then fixed and immuno- 
stained with antibodies to the IL-2 receptor, and the percent- 
age of cells expressing each chimeric receptor that were in- 
hibited in spreading at this time was determined as described 
Figure 7. Inhibition of cell spreading as a function of expression level. (,4) Comparison of the ability of  various chimeric receptors to inhibit 
cell spreading on collagen I as a function of their expression level. Cells transfected with either the/31,/33,/53s, or/55 chimera or the con- 
trol receptor,  C, lacking an intracellular domain were plated on collagen I for 1.5 h. The level of expression of spread and unspread cells 
was determined by photometry and is given in arbitrary units (AU). The ability of the various chimeric receptors to inhibit cell spreading 
when expressed at low levels (0-150 AU), moderate levels (151-300 AU), or high levels (301-600 AU) was determined  as described  in 
Materials and Methods. (B) Comparison of  the ability of transfected cells purified by FACS expressing either moderate (meal) or low levels 
of the/53 or/533 chimera to inhibit cell spreading on collagen I and fibronectin.  When analyzed by photometry,  cells purified by FACS 
with low levels of expression had a mean fluorescence of 122 ALl and cells with moderate levels of expression had a mean fluorescence 
of 280 AU. 
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Figure 8. Inhibition of cell migration. Cells expressing high levels 
of either  the control  receptor (A) or the /31 chimera  (B) were 
purified  by fluorescence-activated cell  sorting  and  plated  on a 
fibronectin substrate. The migration of individual transfected cells 
was followed by video microscopy for a 10-h period.  Tracings of 
individual cells and their paths of migration are shown. 
in Materials and Methods. As quantitated in Fig. 6, we found 
that expression of either the/$~  or the/$3 chimeric receptor 
inhibited cell spreading on all these matrix proteins, whereas 
the/$5  chimera was  a poor inhibitor, and the/$3B chimera 
and the control receptor lacking an intracellular domain did 
not function as inhibitors of cell spreading.  The intrinsic 
ability of cells to spread, however, was not inhibited, since 
cells transfected by the/$1 chimera were still able to spread 
if the substrate was concanavalin A  (data not shown). 
We next examined the relationship between the level of ex- 
pression of the different chimeric receptors and their ability 
to inhibit endogenous function in short-term cell spreading 
assays on a  defined substrate.  Again,  cells transiently ex- 
pressing the various chimeric receptors were not purified by 
FACS but were directly incubated on collagen I for 1.5 h as 
described above. The cells were then immunostained using 
the mAb 4E3 to the IL-2 receptor and the level of expression 
of each chimeric receptor was analyzed in spread and non- 
spread cells by photometry as described in Materials and 
Methods.  The ability of each chimeric receptor to inhibit 
cell spreading as a function of its level of expression is quan- 
titated in Fig. 7 A. These results confirm our previous results 
and furthermore demonstrate that the/$5 chimera can also 
inhibit endogenous integrin function but requires higher lev- 
els of expression as compared with the/$1 and/$3  chimeras. 
Differences in the abilities of low and moderate levels of 
expression of the/$3 and/$3B chimera to inhibit cell spread- 
ing was also demonstrated in transfected cells purified by 
A  B 
I~  P3  ~a  Ps  c  P~  I~  P3a  Ps  c 
Chimeric Rsceptor  Chimeric Receptor 
Figure 9. Inhibition of Cts/~ localization to fibrils and function in 
matrix assembly. Normal human fibroblasts were transiently trans- 
fected with the various chimeric receptors and examined for the dis- 
tribution of either the t~5 subunit (.4) or fibronectin (B) on the cell 
surface of cells spread to similar degrees and expressing moderate 
levels of the chimeric receptors. The localization of cts/~ to fibrils 
was scored as inhibited if its expression was diffuse on the cell sur- 
face. Similarly, matrix assembly was scored as inhibited if  fibronec- 
tin was not detected in fibrils or stitches on the surface of the cell. 
The percent inhibition was calculated as described in Materials and 
Methods. 
FACS.  These results are quantitated in Fig.  7 B and again 
show that the/$3B chimera does not act as an inhibitor of en- 
dogenous integrin function in cell spreading. In contrast, at 
low levels of expression, the/53 chimera is a poor inhibitor 
and at higher levels of expression effectively  inhibits endoge- 
nous integrin function in cell spreading both on fibronectin 
and collagen I substrates. 
Inhibition of CeU Migration 
The ability of high levels of expression of the/$~ chimera to 
inhibit cell migration was also examined. Cells expressing 
high levels of either the/$1  chimera or the control receptor 
purified by FACS as in Fig. 5 were also analyzed by time- 
lapse video microscopy. Cells expressing high levels of the 
control receptor were observed to spread and migrate (Fig. 
8 A), whereas cells expressing high levels of the/31 chimera 
remained round and did not migrate (Fig. 8 B). Rates of cell 
migration were digitized, and they confirmed that expression 
of  the  chimera  containing  the  /sin cytoplasmic  domain 
caused a large inhibition of migration: cells expressing high 
levels of the control receptor lacking any cytoplasmic do- 
main had a migration rate of 3.2 +  2.8 #m/h, whereas trans- 
fectants expressing high levels of the/$~ domain migrated at 
only 0.068  +  0.09 #m/h,  (n  =  29 and 28,  respectively; P 
<  .0001);  the average migration rate was decreased by 50- 
fold in the presence of the/sin cytoplasmic domain. There- 
fore high levels of expression of the/$m chimera not only in- 
hibited cell spreading but also cell migration. 
Inhibition of ~[31 Fibronectin Receptor Localization to 
Fibrils and Function in Matrix Assembly 
Since the 0t5/$~ fibronectin receptor has been shown to be 
involved in matrix assembly in culture (1, 22, 45, 53, 68, 70), 
and at relatively low levels of expression, the/$~,/$3,  and/$5 
chimeric  receptors  colocalized with  endogenous  t~5/$~ at 
fibrils (Fig. 3), we also tested the possibility that at higher 
levels of expression, these chimeric receptors might inhibit 
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transfected ceils purified by FACS. Normal hu- 
man  fibroblasts  were  transiently  transfected 
with various chimeric receptors and then were 
sorted  into  low  or  moderate  expressors  by 
FACS. Cells expressing either low levels of the 
/~ chimera (A) or moderate levels of either the 
B3 chimera (B), the ~3e chimera (C), or the ~5 
chimera  (D)  were  plated  on  coverslips  in 
serum-containing medium for 15 h and then 
immunostained  with  FITC-conjugated  poly- 
clonal antibodies to human fibronectin. When 
the sorted cells expressing low and moderate 
levels of the transfected receptors  were ana- 
lyzed by photometry, the low expressors had a 
mean fluorescence of 122 AU and the moderate 
expressors had a mean fluorescence of 280 AU. 
Bar, 10/~m. 
o~/~t localization to fibrils or matrix assembly itself. To test 
this possibility, normal human fibroblasts were transiently 
transfected with the various chimeric receptors, and 24 h 
later, these cells were replated on unblocked coverslips in 
serum-containing medium  for  15  h.  By double-label im- 
munofluorescence, the distribution of ad3~ and fibronectin 
was determined on individual cells expressing moderate lev- 
els of the chimeric receptor.  (It is  important to note that 
while  moderate  levels  of  expression  of  the  /3~  and  /~3 
chimeras inhibit cell spreading during 1-1.5 h assays, high 
levels of expression of these chimeric receptors are required 
to inhibit cell spreading in the 15 h assays used to analyze 
matrix assembly.) The expression of a chimeric receptor was 
scored as  inhibiting  o~5~ localization or inhibiting matrix 
assembly  on  individual  cells  if the  distribution  of or5  or 
fibronectin was diffuse and not concentrated in stitches or in 
a fibrillar pattern (see Materials and Methods). The ability 
of various chimeric receptors to function as inhibitors in 
these processes is quantitated in Fig. 9. The ~t and/33  chi- 
meric  receptors  inhibited  the  localization  of the  0~5~ to 
fibrils and  also inhibited fibronectin matrix assembly,  al- 
though to a lesser degree. The/3s chimera, the/33B chimera 
and  the  control receptor lacking  an  intracellular  domain 
showed little if any inhibition at these levels of expression. 
Differences in the ability of the/33, ~3~, and ~5 chimeras 
to inhibit matrix assembly, when expressed at moderate lev- 
els, was confirmed in transfected cells purified by FACS (Fig. 
10).  Although the ~3  chimera was  a  poor inhibitor when 
expressed at low levels (Fig.  10 A), moderate levels of the 
B3 chimera did inhibit matrix assembly (Fig. 10 B). In con- 
trast, the/33B and ~5 chimeras were not effective inhibitors 
when expressed at similar levels (Fig.  10, C and D). When 
randomly selected cells were analyzed for matrix assembly, 
only 5/50 cells expressing low levels of the/33 chimera were 
inhibited, whereas 34/50 cells expressing moderate levels of 
the/~3 chimera were inhibited.  In contrast, only  1/50 and 
4/50  cells  expressing  moderate  levels  of the  /33B, or  ~5 
chimeras, respectively, were inhibited in matrix assembly. 
Differences in the ability of the ~3 and/33B chimeras to in- 
hibit  us~  localization  to  fibronectin  fibrils  were  also 
confirmed in these same ceils purified by FACS: oes/~ local- 
ization was inhibited in only 2/50 cells expressing moderate 
levels of the ~3B chimera,  whereas  10/50 and 44/50 cells 
expressing  low  or  moderate  levels  of  the  /33  chimera, 
respectively, had the inhibited phenotype. 
Discussion 
Integrin intracellnlar domains are an important link in the 
pathway by which cells respond to their extracellular matrix. 
Understanding how the extracellular matrix can affect cell 
behavior requires the definition and comparison of integrin 
intracellular domain function, as well as the determination 
of how this function is regulated. To this end, we have ex- 
pressed various  B intracellular domains  as  single-subunit 
chimeric receptors and tested the ability of these chimeras 
to mimic or inhibit specific aspects ofintegrin receptor func- 
tion. Using this approach, we have compared the ability of 
different ~ intracellniar domains to direct receptor localiza- 
tion and have defined a role for alternative splicing in regnlat- 
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the localization of ligand-occupied integrins suggested that 
their/3 intracellular domains can interact with cytoplasmic 
complexes in a ligand-independent or a constitutively "ac- 
five" manner.  If the hypothesis were correct,  this ability 
should also allow these chimeric receptors to function as 
dominant negative mutants and inhibit endogenous integrin 
function;  in  fact,  we  found that  single-subunit chimeric 
receptors could inhibit endogenous integrin localization and 
integrin  functions in  cell  spreading,  cell  migration,  and 
fibronectin matrix  assembly.  Furthermore,  we  have  also 
demonstrated that individual/3 intracellular domains display 
specificity in their ability to mimic and inhibit these aspects 
of integrin function. 
We found that the/33 and/35 chimeras, like the/3~  chi- 
mera, colocalized with endogenous integrins at focal adhe- 
sions and at sites where fibronectin fibrils associate with the 
plasma membrane, indicating that the/33 and/35 intracellu- 
lar domains can also direct receptor localization. The ability 
of the/33 chimera to concentrate at focal adhesions is con- 
sistent with previous reports demonstrating the ability of en- 
dogenous/33  integrins to localize at these sites (18, 20, 61), 
as well as the observation that the function of the/31 and/33 
intracellular domains can be interchangeable in this process 
(63).  There have been, however, contrasting reports regard- 
ing the ability of endogenous/35 integrins to concentrate at 
focal adhesions (15, 50,  67; also see Stuiver,  I., and J. W. 
Smith. 1993. Mol.  Cell.  Biol. 4[Suppl.] 285a). Our results 
with the/35 chimera are consistent with the notion that the 
/35 intracellular domain can also direct receptor localization 
to focal adhesions, but may differ in its ability to do so com- 
pared with the/3~ and/33  intracellular domains. 
The ability of the/33  and/35  chimeras to colocalize with 
endogenous o~5/31 at sites where fibronectin fibrils associate 
with the plasma membrane suggests that the/33 and/35 intra- 
cellular domains, like the/3t intracellular domain, can bind 
to similar cytoplasmic components as as/3t at these sites, 
although  the  /35  intraceilular  domain  appears  to  have  a 
lower affinity for these interactions. The apparent lack of 
colocalization of endogenous /33  and /35 integrins with /3~ 
integrins  at  fibronectin  fibrils  may be  due  to  functional 
differences in their extraceilular domains, especially since 
there is no evidence as yet that any integrins other than mem- 
bers of the/31 subfamily can function in fibronectin matrix 
assembly (1, 22, 45,  53, 68, 70). 
In contrast to the other/3 chimeras, the/33B chimera was 
expressed diffusely on the cell surface and did not concen- 
trate in focal adhesions or at sites of association of fibronec- 
tin with the plasma membrane, indicating that alternative 
splicing can regulate integrin distribution by altering intra- 
cellular interactions.  A  protein  corresponding to  the /33B 
variant mRNA has not yet been characterized, so the effect 
of this variant intracellular domain on heterodimer function 
is not yet known. However, our results would lead us to pre- 
dict that heterodimers containing this variant intracellular 
domain will not concentrate at focal adhesions due to their 
inability to interact with the appropriate cytoskeletal pro- 
teins. Interestingly, a  similar splicing variant has been de- 
scribed for the /31  intracellular domain (4),  and heterodi- 
mers containing a  recombinant form of this/31  variant do 
not concentrate in focal adhesions (6). 
Our results also demonstrate that the/3~ and/33 chimeras 
can function as dominant negative mutants and inhibit en- 
dogenous integrin localization and function. When we com- 
pared the levels of expression of the/3~ chimera with the en- 
dogenous/3~  subunit, we found that in 15 h assays, the/51 
and/33 chimeras could inhibit cell spreading and cell migra- 
tion when expressed at 1-10 times the level of  the endogenous 
/3~  subunit.  Lower levels of expression of the /3~  and /33 
chimeras were required to inhibit matrix assembly. Further- 
more, lower levels of expression of the chimeric receptors 
were required to inhibit cell spreading in 1-1.5 h assays as 
compared to 15 h assays. 
We also found that/3 intracellular domains differ in their 
ability to inhibit endogenous integrin function. Higher levels 
of expression of the/35 chimera were required to inhibit cell 
spreading  as  compared  to  the  /3~  and 133  chimeras.  This 
finding is consistent with reported differences in the abilities 
of  endogenous  /33  and  /35  integrins  to  function  in  cell 
spreading (40).  Furthermore, the/33B chimera did not in- 
hibit endogenous integrin function at any of the expression 
levels examined. 
The ability of the/3~ chimera to inhibit matrix assembly 
suggests that there is a requirement for the integrin/31  but 
not  the  o~5  intracellular  domain  in  matrix  assembly  in 
agreement with previous reports (17, 68).  In addition, the 
/3~ and/33 chimeras always inhibited matrix assembly to a 
lesser extent than ot5/31 localization to fibrils.  This differ- 
ence may be because the redistribution of ot5/31 and/or its 
concentration at fibrils requires a stable interaction between 
the o~5/3m integrin and the cytoskeleton, whereas matrix as- 
sembly may require only more transient interactions. In con- 
trast to the /31  and /33  chimeras,  the/35  chimera was ob- 
served to colocalize with ,5/3~ at fibronectin fibrils, but not 
to inhibit o~5/3~ localization or function, suggesting that the 
135  chimera can bind to  cytoplasmic components already 
concentrated at these sites, but not with sufficient affinity to 
compete successfully with the/3t intracellular domain for 
their binding. 
The mechanism of inhibition by the chimeric receptors in 
these processes  is not yet known.  Inhibition may involve 
competition with specific integrin-cytoskeletal interactions. 
However,  signal transduction events might also be required 
to trigger cell spreading, cell migration and matrix assembly. 
If these events involve integrins, they could also be targets 
for inhibition. In addition, it is important to note that the 
proportions of total endogenous integrin receptors that are 
actually directly involved in any particular biological process 
such as cell spreading or matrix assembly are likely to be 
relatively low at any particular time (e.g.,  10-20%,  as re- 
cently reported  for  interactions of 131  integrins  with  the 
dense extracellular matrix of chick embryo fibroblasts; 19). 
Consequently, the ratio of chimeric molecules to ligand- 
occupied integrin molecules is probably considerably higher 
than to total integrin molecules. Furthermore integrin-cyto- 
skeletal  interactions  required  in  these  processes  may be 
specific for ligand-occupied integrins. Therefore, chimeric 
receptors  may be  in  excess  and competitively inhibiting 
ligand-occupied integrins rather than the whole population 
of integrins. 
The specific intracellular interactions involved in these 
processes have not yet been defined. Detailed mutational 
analysis of the /3~  intracellular domain has defined three 
regions of the 131  intracellular domain, designated cyto 1, 
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ization  in  focal  adhesions  (52),  although  mechanisms 
responsible for the effects of these mutations are not yet un- 
derstood.  Nonetheless,  in vitro binding sites for c~-actinin 
overlap with these regions (47) and a synthetic peptide over- 
lapping cyto 2 can inhibit the in vitro binding of talin to inte- 
grins (64).  These results suggest that talin and/or tx-actinin 
function in receptor localization to focal adhesions consis- 
tent with the observations that tx-actinin and talin colocalize 
with integrins at these sites in tissue culture (reviewed in ref- 
erence 11). Whether interactions of integrins with ot-actinin 
and talin are involved in cell spreading, matrix assembly, or 
cell migration is not yet known. However, rnlcroinjection of 
antibodies against talin have been found to inhibit both cell 
spreading  and cell migration,  implying  a role for talin in 
these two processes (46). Our results also suggest that simi- 
lar interactions are required for both cell migration and cell 
spreading, although it is possible that intracellular interac- 
tions in addition to those involved in cell spreading are re- 
quired for cell migration (e.g.,  see reference 58). 
In summary, we found that relatively high levels of expres- 
sion of the B~ and B3 chimeras could effectively inhibit en- 
dogenous integrin function.  We also found that some pro- 
cesses were more easily inhibited than  others and some B 
chimeras were better inhibitors than others. If inhibition oc- 
curs by the competition of the B chimera for cytoskeletal or 
cytoplasmic proteins required for function, it is reasonable 
that  some processes  would be  inhibited more easily  than 
others  depending  on  the  intracellular  concentration,  and 
possible local concentration, of these components./~ intra- 
cellular  domains  will  likely  contain  overlapping  binding 
sites  for  several  cytoplasmic  proteins,  each  involved  in 
specific integrin-mediated processes.  The identity of these 
proteins, their sites of interaction with/3 intracellular do- 
mains and how these interactions are regulated to mediate 
specific processes are central to understanding  integrin in- 
tracellular function. Our results  define a new approach that 
allows  analysis  of integrin  intracellular  function  without 
complications due to other aspects of heterodimer function. 
Furthermore,  the  ability  of the  different intracellular  do- 
mains  to  cross-inhibit  each  other's  function  to  differing 
degrees  will  allow  comparisons  of  integrin  intracellular 
functions. 
The authors would like to thank Neil J. Hardegen (Laboratory of Immunol- 
ogy in the National Institute of Dental Research) for valuable expertise and 
assistance with  fluorescence-activated cell  sorting  and  flow  cytometric 
analysis, Christopher Yaen and Michael Tran for valuable technical as- 
sistance, our colleague Dr. Robert Lafrenie in the Laboratory of Develop- 
mental Biology for his helpful comments during the preparation  of the 
manuscript; and Drs. Steven Aldyama, David Cheresh, Hynda Kleinman, 
and Warren Leonard for providing necessary materials. 
Received for publication 18 February  1994 and in revised form 20 June 
1994. 
References 
1. Akiyama, S. K., S. S. Yamada, W.-T. Chen, and K. M. Yamada. 1989. 
Analysis of fibronectin receptor function with monoclonal antibodies: 
Roles in cell adhesion, migration, matrix assembly, and cytoskeletal or- 
ganization. J.  Cell Biol.  109:863-875. 
2. Akiyama, S. K., K. Nagata, and K. M. Yamada. 1990. Cell surface recep- 
tors  for  extraceilular  matrix  components.  Biochim. Biophys. Acta. 
1031:91-110. 
3. AIbelda, S. M., and C. A. Buck. 1990.  Integrins and other cell adhesion 
molecules. FASEB (Fed. Am.  Soc. Exp. Biol.) J.  4:2868-2880. 
4. Altruda, F., P. Cervella, G. Tarone, C. Botta, F. Balzac, G. Stefanuto, and 
L. Silengo. 1990.  A human integrin/~1  subunit with a unique cytoplas- 
mic  domain generated by  alternative  mRNA processing.  Gene.  95: 
261-266. 
5. Argraves, W. S., S. Suzuki, H. Ami, K. Thompson, M. D. Pierschbacher, 
and E. Ruoslahti. 1987. Amino acid sequence of the human fibronectin 
receptor. J.  Cell Biol.  105:1183-1190. 
6. Balzac, F., A. M. Belkin, V. E. Koteliansky, Y. V. Balabanov, F. Altruda, 
L. Silengu, and G. Tarone. 1993. Expression and functional analysis of 
a cytoplasmic domain variant of the Bl integrin subunit. J.  Cell Biol. 
121:171-178. 
7. Bauer, J. S., J. Varner, C. Schreiner, L. Kornherg, R. Nicholas, and R. L. 
Juliano. 1993. Functional role of the cytoplasmic domain of the integrin 
c¢~ subunit. J.  Cell Biol.  122:209-221. 
8. Briesewitz, R., A. Kern, and E. E. Marcantonio. 1993. Ligand-dependent 
and -independent integrin focal contact localization:  the role of the a 
chain cytoplasmic domain. Mol. Biol. Cell. 4:593-604. 
9. Burridge, K., and L  R. Feramiseo. 1980. Microinjection and localization 
ofa 130K protein in living fibroblasts: a relationship to actin and fibronec- 
tin.  Cell. 19:587-595. 
10. Burridge, K., and L. Connell. 1983. Talin: a cytoskeletal component con- 
centrated in adhesion plaques and other sites of actin-membrane interac- 
tion. Cell Motil.  3:405-417. 
11. Burridge, K., K. Fath, T. Kelly, G. Nuckolls, and C. Turner. 1988. Focal 
adhesions: Transmembrane junctions between the extraceilular matrix 
and the cytoskeleton. Annu. Rev.  Cell Biol. 4:487-525. 
12. Chart, B. M., P. D. Kassner, L A. Schiro, H. R. Byers, T. S. Kupper, and 
M.  E. Hemier.  1992.  Distinct cellular functions mediated by different 
VLA integrin a  subunit cytoplasmic domains. Cell. 68:1051-1060. 
13. Chen, W.-T., and S. J. Singer. 1982. Immunoelectron microscopic studies 
of the sites of cell-substratum and cell--cell contucts in cultured fibro- 
blasts. J.  Cell Biol.  95:205-222. 
14. Cheresh,  D.  A.  1992.  Structural  and  biologic  properties  of integrin- 
mediated cell adhesion. Clin. Lab. Med.  12:217-236. 
15. Conforti, G., M.  Calza, and A.  Beltran-Nunez.  1994.  c~gs integrin is 
localized at focal contacts by HT-1080 fibrosarcoma  cells and human skin 
fibrnhlasts attached to vitronectin. Cell Ad.  Commun.  1:279-293. 
16. Damsky, C. H., and Z. Werb. 1992. Signal transduction by integrin recep- 
tors for extracelhilar matrix: cooperative processing of extracellular in- 
formation. Curr. Opin. Cell Biol. 4:772-781. 
17. Darribere, T., K. Guida, H. Larjava, K. E. Johnson, K. M. Yamada, J. P. 
Thiery, and J.-C. Boucant. 1990. In vivo analyses of integrin Bz subunit 
function in fibroncctin matix assembly. J.  Cell Biol. 110:1813-1823. 
18. Dejana, E., S. Colella, G. Conforti, M. Abbadini, M. Gaboli, and P. C. 
Marchisio. 1988. Fibronectin and vitronectin regulate the organization of 
their respective Arg-Gly-Asp adhesion receptors in cultured human en- 
dothelial  cells. J.  Cell Biol. 107:1215-1223. 
19. Enomoto-lwamoto, M., A. S. Menko, N. Philp, and D. Boettiger.  1993. 
Evaluation of integrin molecules involved in substrate adhesion.  Cell 
Adh.  Commun.  1:191-202. 
20. Fath, K. R., C.-J. Edgell, and K. Burridge. 1989. The distribution of dis- 
tinct integrins in focal contacts is determined by the substratum  composi- 
tion. J.  Cell Sci. 92:67-75. 
21. Fitzgerald, L. A., B. Steiner, S. C. Pall Jr., S.-S. Lo, and D. R. Phillips. 
1987.  Protein sequence of endothelial glycoprotein Ilia derived from a 
eDNA clone. J.  Biol. Chem. 262:3936--3939. 
22. Fogerty, F. J., S. K. Akiyama, K. M. Yamada, and D. F. Mosher. 1990. 
Inhibition of binding of fibroneetin to matrix assembly sites by anti- 
integrin (a~Bt) antibodies. J.  Cell Biol. 111:699-708. 
23. Geiger, B., D. Salomon, M. Takeichi, and R. O. Hynes. 1992. A chimeric 
N-cadherin/B~-integrin  receptor  which localizes to  both cell-cell  and 
cell-matrix adhesions. J.  Cell Sci. 103:943-951. 
24. Ginsberg, M. H., X. Du, and E. F. Plow. 1992. Inside-out integrin signal- 
ling. Curr. Opin. Cell Biol. 4:766-771. 
25. Giordano,  T.,  T.  H.  Howard,  J.  Coleman, K.  Sakamoto,  and  B.  H. 
Howard. 1991. Isolation of a population of transiently transfected quies- 
cent and senescent cells by magnetic affinity cell sorting. Exp.  Cell Res. 
192:193-197. 
26. Goldstein, S., C. M. Fordis, and B. H. Howard. 1989. Enhanced transfec- 
tion efficiency and improved cell survival after electroporation of G2/M- 
synchronized cells and treatment with sodium butyrate. Nucleic Acids 
Res.  17:3959-3971. 
27. Guan, J. L., J. E. Trevithick, and R. O. Hynes. 1991. Fibronectin/integrin 
interaction  induces tyrosine phosphorylation of a  120-kD protein.  Cell 
Regul. 2:951-964. 
28. Hanks, S. K., M. B. Calalb, M. C. Harper, and S. K. Patel.  1992.  Focal 
adhesion protein tyrosine kinase phosphorylated in response to cell at- 
tachment to fibronectin. Proc. Natl. Acad.  Sci. USA. 89:8487-8491. 
29. Hayashi, Y., B. Haimovich, A. Reszka, D. Boettiger, and A. Horwitz. 
1990. Expression and function of chicken integrin B~ subunit and its cy- 
toplasmic domain mutants in mouse 3T3 cells. J. CellBiol.  110:175-184. 
30. Hemler, M. E. 1990. VLA proteins in the integrin family: structures, func- 
tions and their role on leukocytes. Annu. Rev. lmmunol.  8:365-400. 
31. Hibbs, M. L., H. Xu, S. A. Stacker, and T. A. Springer. 1991. Regulation 
LaFlamme et al.  Chimeras as Mimics and lnhibitom  of lnteerin  Function  ! ~97 of adhesion ICAM-1 by the cytoplasmic domain of LFA-1 integrin 13 
subunit. Science  (Wash. DC).  251:1611-1613. 
32. Hogg, N.  1991.  An integrin overview. Chem. Immunol.  50:1-12. 
33. Hynes, R. O. 1992. Integrins: versatility, modulation, and signaling in cell 
adhesion. Cell. 69:11-25. 
34. Izzard, C. S., and L. R. Lochner. 1976. Cell-to-substrate contacts in living 
fibroblasts:  an interference reflexion study with an evaluation of the tech- 
nique. J.  Cell Sci. 21:129-159. 
35. Johnson, G. D., and (3. M. Nogueira Araujo. 1981.  A simple method of 
reducing the fading of immunofluorescence during microscopy. J.  lm- 
munol.  Methods. 43:349-350. 
36. luliano, R. L., and S. Haskill. 1993. Signal transduction from the extracel- 
lular matrix.  J.  Cell Biol. 120:577-585. 
37. Kassner, P. D., and M. E. Hemler. 1993. Interchangeable alpha chain cyto- 
plasmic domains play a positive role in control of cell adhesion mediated 
by VLA-4, a 13~ integrin. J.  Exp. Med.  178:649-660. 
38. Kawaguchi, S., and M. E. Hemler. 1993. Role of the ~ subunit cytoplasmic 
domain  in  regulation of adhesion activity  mediated by  the  integrin 
VLA-2. J.  Biol. Chem. 268:16279-16285. 
39. LaFlamme, S. E., S. K. Akiyama, and K. M. Yamada. 1992. Regulation 
of fibronectin receptor distribution. J.  Cell Biol. 117:437-447. 
40. Leavesley, D. I., G.  D. Ferguson, E.  A. Wayner, and D. A. Cheresh. 
1992.  Requirement of the integrin 133 subunit for carcinoma cell spread- 
ing or migration on vitronectin and fibrinogen. J.  Cell Biol.  117:1101- 
1107. 
41. Leonard, W. J., J. M. Depper, G. R. Crabtrce, S. Rudikoff, J. Pumphrey, 
R. J. Robb, M. Kronke, P. B. Svetlik,  N. J. Peffer,  T. A. Waldmann, 
and W. C. Greene. 1984.  Molecular cloning and expression of cDNAs 
for the human IL-2 receptor. Nature  (Lond.).  311:626-631. 
42. Marcantonio, E. E., J.-L. Guan, J. E. Trevithick, and R. O. Hynes. 1990. 
Mapping of the functional determinants of the integrin/3~  cytoplasmic 
domain by site-directed mutagenesis. Cell Regul.  1:597-604. 
43. McLean, J. W., D. J.  Vestal, D. A. Cheresh, and S. C. Bodary.  1990. 
cDNA  sequence of the  human integrin  /35  subunit.  J.  Biol. Chem. 
265:17126-17131. 
44. Miekka, S. I., K. C. Ingham, and D. Menache. 1982. Rapid methods for 
isolation of human plasma fibronectin.  Thromb. Res.  27:1-14. 
45. Mosher, D. F., J. Sottile,  C. Wu, and J. A. McDonald.  1992. Assembly 
of extracellular matrix. Curr. Opin. Cell Biol.  4:810-818. 
46. Nuckoils, G. H., L. H. Romer, and K. Burridge. 1992. Microinjection of 
antibodies against talin inhibits the spreading and migration of fibroblasts. 
J.  Cell Sci.  102:753-762. 
47. Otey, C. A., G. B. Vasquez, K. Burridge, andB. W. Erickson. 1993. Map- 
ping of the ct-actinin binding site within the ~  integrin cytoplasmic do- 
m~n. J.  Biol.  Chem. 268:21193-21197. 
48. O'Toole, T. E., D. Mandelman, J. Forsyth, S. J. Shattil,  E. F. Plow, and 
M.  H.  Ginsberg.  1991.  Modulation of the affinity  of integrin cdI~3 
(GPIIb-IIIa)  by the cytoplasmic domain of alIb.  Science  (Wash. DC). 
254:845-847. 
49. O'Toole, T. E., Y. Katagiri, R. J. Fanll, K. Peter, R. Tamura, V. Quaranta, 
J. C. Loftus, S. J. Shattill,  and M. H. Ginsberg. 1994. Integrin cytoplas- 
mic domains mediate inside-out signal transduction. J.  Cell Biol. 124: 
1047-1059. 
50. Pasqualini, R., and M.  Hemier.  1994.  Contrasting roles for integrin ~ 
and /~5 cytoplasmic domains in subceilular localization,  cell  prolifera- 
tion, and cell migration. J.  Cell Biol. 125:447-460. 
51. Ramaswamy, H., and M. E. Hemier. 1990. Cloning, primary structure and 
properties of a novel human integrin/~ subunit. EMBO (Eur. Mol. Biol. 
Organ.) J.  9:1561-1568. 
52. Reszka, A. A., Y. Hayashi, and A. F. Horwitz.  1992.  Identification  of 
amino acid sequences in the integrin ~  cytoplasmic domain implicated 
in cytoskeletal association. J.  Cell Biol.  117:1321-1330. 
53. Roman, J., R. M. LaChance, T. J. Broekelmann, C. J. Kennedy, E. A. 
Wayner, W.  G.  Carter,  and J.  A.  McDonald.  1989.  The fibronectin 
receptor is organized by extracellular matrix fibronectin:  implications for 
oncogenic transformation and for cell recognition of fibronectin matrices. 
J.  Cell Biol.  108:2529-2543. 
54. Ruoslahti, E.  1991.  Integrins. J.  Clin. Invest. 87:1-5. 
55. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989.  Molecular Cloning: 
A  Laboratory  Manual.  Cold  Spring  Harbor  Laboratory  Press,  Cold 
• Spring Harbor, NY. 
56. Sastry, S.  K., and A. F. Horwitz.  1993.  Integrin cytoplasmic domains: 
mediators of cytoskeletal linkages and extra- and intracellular initiated 
transmembrane signaling. Curr. Opin. Cell Biol. 5:819-831. 
57. Schaller, M. D., C. A. Borgman, B. S. Cobb, R. R. Vines, A. B. Reynolds, 
and J.  T. Parsons.  1992.  ppI25FAK a structurally distinctive protein- 
tyrosine kinase associated with focal adhesions. Proc. Natl. Acad.  Sci. 
USA. 89:5192-5196. 
58. Schmidt, C. E., A. F. Horwitz, D. A. Lauffenburger, and M. P. Sheetz. 
1993.  Integrin-cytoskeletal interactions in migrating fibroblasts are dy- 
namic, asymmetric, and regulated. J.  Cell Biol.  123:977-991. 
59. Sharon,  M.,  R.  D.  Klausner, B.  R.  Cullen, R.  Chizzonite, and W.  J. 
Leonard. 1986. Novel IL-2 receptor subunit  detected by cross-linking  un- 
der high-affinity conditions. Science  (Wash. DC). 234:859-863. 
60. Singer, I. L, and P. R. Paradiso. 1981. A transmembrane relationship be- 
twcen fibronectin and vinculin (130 kd Protein):  serum  modulation in nor- 
mal and transformed hamster fibroblasts. Cell. 24:481-492. 
61. Singer, I. I., S. Scott, D. W. Kawka, D. M. Kazazis, J. Gaifit, and E. Ruos- 
lahti. 1988. Cell surface distribution of fibronectin and vitronectin recep- 
tors depends on substrate composition and extracellniar matrix accumula- 
tion. J.  Cell Biol. 106:2171-2182. 
62. Solowska, J., J.-L. Guan, E. E. Marcantonio, J. E. Trevithick, C. A. Buck, 
and R. O. Hynes. 1989. Expression of normal and mutant avian integrin 
subunits in rodent cells. J.  Cell Biol. 109:853-861. 
63. Solowska, J., J. M. Edelman, S. M. Albeida, and C. A. Buck. 1991. Cyto- 
plasmic and transmembrane domains of integrin BJ and ~3 subunits are 
functionally interchangeable. J.  Cell Biol. 114:1079-1088. 
64. Tapley, P., A. Horwitz, C. Buck, K. Duggan, and L. Rohrschneider. 1989. 
Integrins isolated from Rous sarcoma virus-transformed chicken embryo 
fibroblasts. Oncogene. 4:325-333. 
65. Thomas, L.  A., and K. M.  Yamada.  1992.  Contact stimulation of cell 
migration. J•  Cell Sci.  103:1211-1214. 
66. van Kuppevelt, T. H., L. R. Languino, J. O. Gallit, S. Suzuki, and E. Ruos- 
lahti.  1989.  An  alternative  cytoplasmic  domain  of  the  integrin  133 
subunit. Proc.  Natl. Acad.  Sci. USA. 86:5415-5418. 
67. Wayner, E. A., R. A. Orlando, and D. A. Cheresh. 1991.  Integrins (xv133 
and (xd3s contribute to cell  attachment to vitronectin but differentially 
distribute on the cell surface. J.  Cell Biol. 113:919-929. 
68. Wu, C., J. S. Bauer, R. L. Juliano, and J. A. McDonald. 1993. The (x513~ 
integrin fibronectin receptor, but not the a5 cytoplasmic domain, func- 
tions in an early and essential step in fibronectin matrix assembly. J. Biol. 
Chem. 268:21883-21888. 
69. Ylanne, J., Y. Chen, T. E. O'Toole, J. C. Loftus, Y. Takada, and M. H. 
Ginsberg. 1993. Distinct functions of integrin o~ and/3 subunit cytoplas- 
mic domains in cell spreading and formation of focal adhesions. J.  Cell 
Biol.  122:223-233. 
70. Zhang, Z., A. O. Morla, K. Vuori, J. S. Bauer, R. L. Juliano, and E. Ruos- 
lahti.  1993.  The ~v/3~ integrin functions as a  fibronectin receptor but 
does not  support fibronectin matrix assembly and  cell  migration on 
fibronecfin.  J.  Cell Biol. 122:235-242. 
The Journal of Cell Biology, Volume 126,  1994  1298 